azido(2-pyridin-4-ylthiazol-4-yl)methanone | 21278-94-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: azido(2-pyridin-4-ylthiazol-4-yl)methanone
• 英文别名: 2-pyridin-4-yl-thiazole-4-carbonyl azide；2-(4-pyridinyl)-4-thiazolylcarbonylazide；2-(Pyridyl-4)-thiazol-carbonsaeure-4-azid；2-pyridin-4-yl-1,3-thiazole-4-carbonyl azide
• CAS: 21278-94-4
• 化学式: C₉H₅N₅OS
• 分子量: 231.238
• InChiKey: SQBRLKYNLBHLNS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  85.4
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  azido(2-pyridin-4-ylthiazol-4-yl)methanone 、 3-(氨基甲基)吡啶-2-胺 以 甲苯 为溶剂， 生成 1-(3-Amino-pyridin-2-yl)-3-(2-pyridin-4-yl-thiazol-4-yl)-urea
  参考文献：
  名称：

  Thiazolyl urea compounds and methods of uses

  摘要：

  选定的新型尿素化合物对预防和治疗疾病有效，如细胞增殖或凋亡介导的疾病。该发明涵盖了新型化合物、类似物、前药和其药用可接受的盐，以及用于预防和治疗中风、癌症等疾病和其他疾病或病况的药物组合物和方法。该发明还涉及制备此类化合物的方法，以及在这些过程中有用的中间体。

  公开号：

  US20020193405A1
• 作为产物：
  描述：

  2-(4-吡啶基)噻唑-4-羧酸 在 sodium azide 、 三乙胺 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 3.08h， 生成 azido(2-pyridin-4-ylthiazol-4-yl)methanone
  参考文献：
  名称：

  Novel Tetrahydropyrido[1,2-a]isoindolone Derivatives (Valmerins): Potent Cyclin-Dependent Kinase/Glycogen Synthase Kinase 3 Inhibitors with Antiproliferative Activities and Antitumor Effects in Human Tumor Xenografts

  摘要：

  The development of CDK and GSK3 inhibitors has been regarded as a potential therapeutic approach, and a substantial number-of-diverse structures have been reported to inhibit CDKs and GSK-3 beta. in recent years. Only a few molecules have gone through or are currently undergoing clinical trials as CDK and GSK inhibitors. In this paper, we prepared valmerins, a new family containing the tetrahydropyrido[1,2-a]isoindone core. The fused heterocycle was prepared with a straightforward synthesis that was functionalized by a (het)arylurea. Twelve valmerins inhibited the CDK5 and GSK3 with an IC50 < 100 nM. A semiquantitative kinase scoring was realized, and a cellular screening was done. At the end of study, we investigated the in vivo potency of one valmerin. Mice exhibited good tolerance to our lead, which proved its efficacy and clearly blocked tumor growth. Valmerins appear also as good candidates: for further development as anticancer agents.

  DOI：

  10.1021/jm3008536

文献信息

• Urea compounds and methods of uses
  申请人：——

  公开号：US20020173507A1

  公开（公告）日：2002-11-21

  Selected novel urea compounds are effective for prophylaxis and treatment of diseases, such as cell proliferation or apoptosis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving stoke, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  选择的新型尿素化合物对预防和治疗疾病有效，例如细胞增殖或凋亡介导的疾病。该发明涵盖了新型化合物、类似物、前药和其药用可接受的盐、预防和治疗涉及中风、癌症等疾病和其他疾病或病症的药物组合物和方法。该发明还涉及制备此类化合物的过程以及在此类过程中有用的中间体。
• [EN] THIAZOLYL UREA COMPOUNDS FOR THE TREATMENT OF CANCER<br/>[FR] COMPOSES DE THIAZOLYL UREE POUR LE TRAITEMENT DU CANCER
  申请人：AMGEN INC

  公开号：WO2003070727A1

  公开（公告）日：2003-08-28

  Selected thiazolyl urea compounds of formula (VI) are effective for prophylaxis and treatment of diseases, such as cell proliferation or apoptosis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving stoke, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  公式（VI）的选定噻唑基脲类化合物对预防和治疗细胞增殖或凋亡介导的疾病有效。本发明涵盖新的化合物、类似物、前药和其药学上可接受的盐、药物组合物和预防和治疗中风、癌症等疾病及其他疾病或情况的方法。本发明还涉及制备这种化合物的过程以及在这种过程中有用的中间体。
• Urea compounds as kinase inhibitors
  申请人：Amgen, Inc.

  公开号：EP1619184A2

  公开（公告）日：2006-01-25

  Selected novel urea compounds are effective for prophylaxis and treatment of diseases, such as cell proliferation or apoptosis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving stroke, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  精选的新型脲化合物可有效预防和治疗疾病，如细胞增殖或凋亡介导的疾病。本发明包括新型化合物、类似物、原药及其药学上可接受的盐、药物组合物以及用于预防和治疗涉及中风、癌症等疾病和其他弊病或病症的方法。本发明还涉及制造此类化合物的工艺以及在此类工艺中有用的中间体。
• Structure–activity relationships of 3,4-dihydro-1H-quinazolin-2-one derivatives as potential CDK5 inhibitors
  作者：Robert M. Rzasa、Matthew R. Kaller、Gang Liu、Ella Magal、Thomas T. Nguyen、Timothy D. Osslund、David Powers、Vincent J. Santora、Vellarkad N. Viswanadhan、Hui-Ling Wang、Xiaoling Xiong、Wenge Zhong、Mark H. Norman

  DOI：10.1016/j.bmc.2007.07.005

  日期：2007.10

  Cyclin-dependent kinase 5 (CDK5) is a serine/threonine kinase that plays a critical role in the early development of the nervous system. Deregulation of CDK5 is believed to contribute to the abnormal phosphorylation of various cellular substrates associated with neurodegenerative disorders such as Alzheimer's disease, amyotrophic lateral sclerosis, and ischemic stroke. Acyclic urea 3 was identified as a potent CDK5 inhibitor and co-crystallographic data of urea 3/CDK2 enzyme were used to design a novel series of 3,4-dihydroquinazolin-2(1H)-ones as CDK5 inhibitors. In this investigation we present our synthetic studies toward this series of compounds and discuss their biological relevance as CDK5 inhibitors. (c) 2007 Elsevier Ltd. All rights reserved.
• Benkoe,A.; Levente,A., Justus Liebigs Annalen der Chemie, 1968, vol. 717, p. 148 - 153
  作者：Benkoe,A.、Levente,A.

  DOI：——

  日期：——